Hair loss is a real but likely reversible side effect of GLP-1 medications. The primary cause appears to be telogen effluvium — a form of temporary hair shedding triggered by rapid weight loss, not a direct drug toxicity.
FAERS data shows semaglutide and tirzepatide have higher reporting odds for alopecia than older GLP-1s. In Wegovy clinical trials, 2.5% of patients reported hair loss vs. 1.0% on placebo. Most dermatologists say the shedding is temporary and can be mitigated with proper nutrition.
The FDA Adverse Event Data
Multiple pharmacovigilance analyses have examined the FDA's FAERS database for hair loss signals. The most comprehensive, published in the Journal of the European Academy of Dermatology and Venereology, found:
| GLP-1 Drug | Reporting Odds Ratio (ROR) | Signal? |
|---|---|---|
| Semaglutide | 2.46 | Yes — elevated reporting |
| Tirzepatide | 1.73 | Yes — elevated reporting |
| Liraglutide | 0.61-1.53 | No significant signal |
| Dulaglutide | Not significant | No signal |
| Exenatide | Not significant | No signal |
What this means: Semaglutide and tirzepatide have stronger associations with reported hair loss than older GLP-1s. However, FAERS data shows correlation, not causation — these are also the most popular GLP-1s with the highest prescription volume.
What the Clinical Trials Found
According to a Novo Nordisk statement to CNN:
"In clinical trials of Wegovy, hair loss was reported in 2.5% of Wegovy-treated adult patients vs 1.0% of placebo-treated adult patients. Hair loss was reported more frequently in patients with a greater weight loss (≥20%) suggesting that the events of hair loss were potentially related to the magnitude of weight loss."— Novo Nordisk spokesperson, November 2025
Why It Happens: The Leading Theories
1. Telogen Effluvium (Most Likely)
The medical consensus points to telogen effluvium (TE) — a type of temporary hair shedding triggered by metabolic stress on the body.
"Any time people lose a significant amount of weight, typically in a short period of time, it is well-known that that can trigger an event called telogen effluvium, which basically is an alteration of the hair cycle in which an abnormal percentage of hair follicles enter into the shedding phase."— Dr. Aron Nusbaum, dermatologist and hair restoration surgeon, Miami Hair Institute
TE typically appears 3-6 months after the triggering event (rapid weight loss) and usually resolves within 6-12 months once weight stabilizes.
2. Nutritional Deficiencies
GLP-1 medications reduce appetite significantly, which can lead to deficiencies in nutrients critical for hair health:
- Iron — essential for hair follicle function
- Zinc — supports hair growth and repair
- Biotin — B vitamin for keratin production
- Vitamin D — regulates hair follicle cycling
- Protein — building block for hair structure
3. Possible Direct Effects (Unproven)
Some researchers speculate that GLP-1 receptors exist on hair follicles and may influence the hair cycle directly. However, according to a 2025 review in the Journal of Cosmetic Dermatology, "human data are lacking, necessitating further research."
The Largest Cohort Study
A September 2025 study using TriNetX data analyzed over 547,000 GLP-1 users matched to non-users:
- GLP-1 use was independently associated with increased telogen effluvium
- GLP-1 use was also associated with androgenetic alopecia (pattern hair loss)
- No association was found with alopecia areata (autoimmune hair loss)
"Most hair shedding on GLP-1s looks like androgenetic alopecia unmasked by an episode of telogen effluvium driven by the magnitude of weight loss, rather than a direct drug toxicity."— Dr. Michael Buontempo, Dartmouth-Hitchcock Medical Center
Is It Reversible?
Yes, in most cases. Telogen effluvium is typically temporary. According to dermatologists interviewed by CNN:
- Hair shedding typically begins 6-12 weeks after rapid weight loss starts
- Improvement usually occurs within 3-6 months once weight stabilizes
- Maintaining adequate nutrition can help mitigate the effect
What You Can Do
If You're Starting GLP-1 Treatment
- Set expectations: Temporary shedding is possible, especially with significant weight loss
- Maintain nutrition: Ensure adequate protein, iron, zinc, biotin, and vitamin D intake
- Consider supplements: Discuss with your doctor if nutritional support is appropriate
- Pace weight loss: Slower, steadier weight loss may reduce TE risk
If You're Experiencing Hair Loss
- Don't panic: Most cases resolve on their own
- See a dermatologist: Get proper diagnosis — it may not be TE
- Check labs: Rule out thyroid issues, iron deficiency, vitamin D deficiency
- Discuss with your prescriber: Usually no need to stop medication, but discuss options
The Sources
Peer-Reviewed Studies
- Godfrey H, et al. "Alopecia associated with semaglutide and tirzepatide: A disproportionality analysis using FAERS." JEADV. 2025.
- Haykal D. "Alopecia and Semaglutide: Connecting the Dots for Patient Safety." J Cosmet Dermatol. 2025.
- Desai DD, et al. "GLP-1 Agonists and Hair Loss: A Call for Further Investigation." Int J Dermatol. 2024.
- Buontempo MG. "Exploring the hair loss risk in GLP-1 agonists." JEADV. 2025.
- Systematic Review: "Hair Loss Associated With GLP-1 Receptor Agonist Use." Cureus. 2025.
Expert Interviews & Commentary
Considering GLP-1 Treatment?
Compare verified providers offering semaglutide and tirzepatide.
Compare Providers →Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. If you're experiencing hair loss, consult a dermatologist for proper diagnosis and treatment.